News & Activities

ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness

ProBio CDMO Expands Viral Vector Development Capabilities at US site, Hopewell, New Jersey, with New Packaging Test Platform

ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy

ProBio to Present Data on Its CD3 Agonistic Single Domain Antibody Platform for Accelerated Development of T Cell Engager Multi-Specific Antibodies - ProBio

ProBio Sets New Standard in GMP Plasmid DNA Manufacturing with Guaranteed ≥ 85% Supercoiled DNA, Fixed-Cost, Clinical-Grade Delivered in Just 3 Months

ProBio Congratulates GeneCraft on MFDS Clearance for RX001, the World’s First AAV-Based Lung Cancer Therapy - ProBio

ProBio Announces New Executive Appointments - ProBio

GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer - ProBio

ProBio Accelerates Chimagen’s Global Market Expansion, Paving the Way for Innovative Antibody Therapy - ProBio

ProBio and UCI Therapeutics Sign a Strategic Cooperation MOU for Comprehensive Collaboration in Gene Delivery Technologies, Including Viral and Non-Viral Approaches - ProBio

ProBio Extends Congratulations to InnoBation Bio on MFDS Clearance of IBC101 Program - ProBio

ProBio Signs Collaboration Agreement with Cell Resources Corporation, a Subsidiary of Alfresa Holdings Corporation for Cell Therapy Development - ProBio

ProBio Congratulates TG ImmunoPharma on FDA Clearance of Clinical Trial for TGI-5 Monoclonal Antibody - ProBio

ProBio signs viral vector manufacturing MOU with Curocell for next-generation CAR-T therapy - ProBio

The MOU between ProBio and NuclixBio - ProBio

ProBio Partners with Epi Biotech to Advance Hair Loss Antibody Therapy - ProBio

ProBio Congratulates ABL Bio’s IND Clearance of ABL103 Program from MFDS - ProBio

Dx&Vx Signs Strategic Partnership with ProBio for Novel Drug Development - ProBio

ProBio Congratulates IMBiologics on FDA Clearance of IND Application for Innovative Bispecific Antibody Drug Project (IMB-101) - ProBio

ProBio and Comprehensive Cell Solutions, a Business Unit of the New York Blood Center Enterprises, Form a Pioneering Partnership to Expedite Cell and Gene Therapy Development and Manufacturing - ProBio